Background {#Sec1}
==========

The Femoroacetabular Impingement Randomised controlled Trial (FIRST) is a multi-centre, concealed randomized controlled trial (RCT) evaluating the effect of arthroscopic lavage (i.e. washing out the hip joint) versus osteochondroplasty (i.e. surgical correction of the hip impingement morphology) in adults aged 18--50 years diagnosed with non-arthritic femoroacetabular impingement (FAI). The protocol for the FIRST trial has been previously published \[[@CR1]\] and provides more detail on the trial rationale, eligibility criteria, interventions, data management, and methods for limiting bias.

FAI is a condition that causes hip pain in the young adult as a result of a size and shape mismatch between the femoral head and the acetabulum. FAI is typically classified into two sub-types; cam type (a misshaped femoral head) or pincer type (an over-covered or deep socket). Most patients have a combination of both types of impingement. With FAI, the femoral head (ball) and acetabular rim (socket) of the hip joint collide during hip flexion and rotation. This collision results in an impingement of the femoral head/neck/column on the acetabular rim, and patients experience hip pain. This pain can be a precursor to early hip damage such as cartilage delamination and labral tears of the hip. As the condition progresses, the resulting hip damage may lead to osteoarthritis of the hip \[[@CR1]\].

The rationale for the FIRST trial is based upon (1) an exponential increase in FAI surgery with resultant increased healthcare costs over that last decade, (2) worldwide disparity in perceptions about its utility, and (3) consensus that definitive evidence for or against surgical approaches is lacking. Therefore, the primary objective of the trial is to assess whether surgical correction of the impingement morphology (arthroscopic osteochondroplasty) with or without labral repair, in adults aged 18--50 years diagnosed with non-arthritic FAI, provides decreased pain at 12 months compared to arthroscopic lavage of the hip joint. Secondary objectives include measuring outcomes associated with the intervention and control groups (osteochondroplasty versus lavage) related to improved lifestyle, emotional health, and physical health.

This trial is a parallel multi-centre, blinded randomised controlled trial (RCT) of 220 patients who have been diagnosed with FAI, to determine the superiority of arthroscopic osteochondroplasty to arthroscopic lavage. Briefly, participants were recruited from experienced hip surgeons practicing at 10 participating sites based in Canada, Finland, and Denmark. Patients were allocated to one of two treatment arms using an online centralized 24-h computerised randomisation system. The randomisation system follows a computer-generated randomisation schedule in random block sizes of 4 and 8. Randomisation was stratified by impingement sub-type (cam versus mixed) and clinical centre. Study personnel monitor critical aspects of perioperative care and rehabilitation. We are assessing subject pain within 12 months using a visual analogue scale (VAS) after surgery as the primary outcome. Secondary outcomes include function, health-related quality of life, post-operative complications, and costs. Quality of the surgery and complications, including re-operations, will be reviewed by an independent adjudication committee. Outcome assessors and data analysts are blinded to treatment allocation. The full study process is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Femoroacetabular Impingement Randomised controlled Trial (FIRST) process overview. MRI, magnetic resonance imaging; MRA, magnetic resonance angiography; FAI, femoroacetabular impingement; VAS, visual analogue scale; HOS, Hip Outcome Score; iHOT, International Hip Outcome Tool; SF-12 Short Form-12; EQ-5D, EuroQol-5 Dimensions

In this article, we present our planned statistical analyses for the FIRST trial. The statistical analysis plan was finalized and approved on 29 November 2017 (Version 1.0) for the FIRST trial protocol (20 April 2016, Version 3.0) and in accordance with the trial Masterfile, including the Data Management Plan (June 4, 2014, Version 1.0). Ethics approval was granted at the Methods Centre at McMaster University (Hamilton Integrated Research Ethics Board \#12--396) and at each participating site (as per their local ethics board). The trial is registered at [ClinicalTrials.gov](http://clinicaltrials.gov) (NCT01623843).

Methods {#Sec2}
=======

Outcomes {#Sec3}
--------

### Primary outcome {#Sec4}

The FIRST primary outcome is pain at 12 months as measured by the VAS. The primary analysis is to assess whether surgical correction of the impingement morphology (arthroscopic osteochondroplasty) with/without labral repair, in adults aged 18--50 years diagnosed with FAI, provides decreased pain at 12 months compared to arthroscopic lavage of the hip joint with/without labral repair, as measured by the VAS. The VAS is a validated unidimensional scale that is easy to use, requires no verbal or reading skills, and is sufficiently versatile to be employed in a variety of settings \[[@CR2]--[@CR4]\].

### Secondary outcomes {#Sec5}

Secondary outcomes include:Hip function as measured by the Hip Outcome Score (HOS).Generic physical and mental health as measured by the Short Form-12 (SF-12).Impact of hip-specific disease on function and lifestyle in the young, active patient as measured by the International Hip Outcome Tool (iHOT-12).Health utility as measured by the EuroQol (EQ-5D).Complications, including additional surgery and other serious and non-serious adverse events. Reasons for re-operations for the randomized hip typically include, but are not limited to re-injury of the labrum/cartilage, hip dislocation, hip instability, infection (deep or superficial), wound healing problem, soft tissue problem, and unresolved hip pain. Other hip-related adverse events to be reported include, but are not limited to, hip instability, tendinopathy, re-injury of the labrum/cartilage, hip osteoarthritis post-surgery, and infection (superficial or deep).

The HOS is a self-administered hip score that was designed to capture hip function and outcomes following surgical therapies such as arthroscopy \[[@CR5]\]. The HOS has been shown to have the greatest clinimetric evidence for use in patients with FAI or labral tears \[[@CR6], [@CR7]\]. The SF-12 may be self-completed or interview-administered and will help document general health status and the burden of illness that FAI presents \[[@CR8]\]. The iHOT-12 is a shorter version of the iHOT-33 designed to be easier to complete in routine clinical practice to measure both health-related quality of life and changes after treatment in young, active patients with hip disorders \[[@CR9]\]. This questionnaire has been shown to be valid, reliable, and responsive to change \[[@CR9]\]. The EQ-5D is a standardized instrument for use as a measure of health outcome \[[@CR10]\]. The EQ-5D comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The EQ-5D has been used in previous studies involving patients with hip pain and has been extensively validated \[[@CR11], [@CR12]\].

Discussion {#Sec6}
==========

Analysis plan {#Sec7}
-------------

This statistical analysis plan follows the JAMA Guidelines for the content of statistical analysis plans in clinical trials \[[@CR13]\]. A summary of all planned analyses is provided in Table [1](#Tab1){ref-type="table"}.Table 1Statistical analysis plan summaryObjectiveOutcomeHypothesisMethod of analysis^a^NameTypePrimary objective To compare pain levels at 1 yearPain (VAS)ContinuousOsteochondroplasty will reduce pain compared to lavageMultiple linear regressionSecondary objectives 1 To compare patient-reported health-related quality of lifeHip function (HOS)ContinuousOsteochondroplasty will improve health-related quality of life, function, and utility compared to lavageMultiple linear regressionHip-specific disease on hip function (iHOT-12)ContinuousPhysical health (SF-12 PCS)ContinuousMental health (SF-12 MCS)ContinuousHealth Utility (EQ-5D)ContinuousSecondary objective 2 To compare hip complicationsHip-related complications (e.g. re-operation)BinaryOsteochondroplasty will reduce rate of re-operations compared to lavageMultiple logistic regressionSubgroup analysis Hip impingement severity: mild (alpha angle \< 60 -- \> 50 degrees), moderate (alpha angle \> 60 -- \< 83°), severe (alpha angle \> 83°)Pain (VAS)ContinuousPatients with severe impingement at baseline will have the greatest improvement with the osteochondroplasty procedure compared with those with moderate to mild impingementMultiple linear regression Gender: male, femalePain (VAS)ContinuousThe osteochondroplasty procedure will perform better in malesMultiple linear regression Cartilage status (based on Tonnis and Heinecke classification): grades 3 and 4, grades 1 and 2Pain (VAS)ContinuousOsteochondroplasty will perform worse in patients with worse cartilage status (i.e. grades 3 and 4)Multiple linear regression Treatment of the labrum: labral repair, resectionPain (VAS)ContinuousPatients receiving a labral repair will perform better than those receiving a resection as part of the osteochondroplasty procedureMultiple linear regressionSensitivity analysis Trial site (centre-effects)Pain (VAS)ContinuousWe do not expect the effect to change substantially when centre-effects are removed from the primary analysisMultiple linear regression with centre-effects removed Missing data effectPain (VAS)ContinuousWe do not expect the effect to change substantially without imputation for missing dataMultiple linear regression with complete cases only Potential baseline imbalancePain (VAS)ContinuousResults will remain robust after adjusting for potential baseline imbalance on age, any comorbidities, onset of symptoms, and presence of labral tears at initial surgeryMultiple linear regression with complete cases only\*All regression analyses will be controlled for centre as a stratification variableVAS: Visual Analogue Scale, SF: Short Form, PCS: Physical Component Summary, MCS: Mental Component Summary, HOS:Hip Outcome Score, iHOT: International Hip Outcome Tool, EQ-5D: Euroqol-5 Dimensions

### Blinded analyses {#Sec8}

All statistical analyses will first be completed using blinded treatment groups (i.e. treatment X and Y). Interpretations for the effect of the surgical interventions will be documented based upon blinded X versus Y treatment \[[@CR14]\].

### Presentation of data {#Sec9}

The trial results will be presented according to the Consolidated standards of reporting trials (CONSORT) guidelines for RCTs \[[@CR15]\]. The baseline demographic characteristics and a description of the surgical and peri-operative management characteristics of the patients will be summarized by group, reported as mean (standard deviation (SD)) or median (first quartile, third quartile) for continuous variables and count (percent) for categorical variables (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). All statistical tests will be two-tailed with α = 0.05.Table 2Patient demographics and hip characteristicsTreatment X\
*n* =Treatment Y\
*n* =Patient characteristics Age, mean (SD) Gender, *n* (%)  Male  Female Ethnicity, *n* (%)  Native  Asian  Black  Hispanic  White/Caucasian Smoking history, *n* (%)  Never smoked  Current smoker  Former smoker Alcohol consumption, *n* (%)  No alcohol at baseline  0.5--2 drinks/week  3--5 drinks/week  6--10 drinks/week  11+ drinks/week Current medications, *n* (%)  None  NSAIDS  Intra-articular injection  Etc.... (as per available data) Co-morbidities, *n* (%)  None  Cancer  Back pain  Etc... (as per available data) BMI, *n* (%)  Underweight \< 18.5  Normal weight 18.5--24.9  Overweight 25--29.9  Obese 30--39.9  Morbidly obese 40 or greater Weightbearing status, *n* (%)  Full weightbearing  Partial weightbearing  Non-weightbearing Baseline sport activity, *n* (%)  None  Light  Moderate  VigorousHip characteristics Affected hip, *n* (%)  Left  Right Location of hip pain, *n* (%)  Groin  Lateral  Posterior  Groin and lateral  Groin and posterior  Lateral and posterior  Groin and lateral and posterior Onset of symptoms, *n* (%)  Acute  Subacute  Insidious  Traumatic  Non-traumatic Tonnis and Heinecke classification, *n* (%)  Grade 0  Grade 1  Grade 2  Grade 3 Labral tears present, *n* (%)  None  Anterior  Posterior  Superior/lateral  Anterior and posterior  Anterior and superior/lateral  Posterior and superior/lateral Herniation pits present, *n* (%)  No  Yes*NSAID* non-steroidal anti-inflammatory drug, *BMI* body mass indexTable 3Surgical and peri-operative managementTreatment X\
*n* =Treatment Y\
*n* =Duration of procedure, mean (SD)Duration of traction, mean (SD)Total saline used in procedure, mean (SD)Type of surgical prep solution, *n* (%) Iodine Chlorohexidine Alcohol Etc\... (as per available data)Labral tears, *n* (%) None Partial CompleteLabrum injected, *n* (%) No Yes  Focal  DiffuseOuterbridge intra-operative cartilage classification, *n* (%) Grade 0 Grade 1 Grade 2 Grade 3 Grade 4Beck intra-operative cartilage classification, *n* (%) Grade 0 Grade 1 Grade 2 Grade 3 Grade 4Beck intra-operative labral classification, *n* (%) Grade 0 Grade 1 Grade 2 Grade 3 Grade 4Capsulotomy performed, *n* (%) No Yes  Partial  CompleteCapsular closure performed, *n* (%) Yes NoAnchors used for labrum repair, *n* (%) Not applicable (no repair) 0 1 2 3 4 5 6Antibiotic prophylaxis, *n* (%) No Yes  Cefazolin  Cefuroxime  Vancomycin  OtherThromboprophylaxis, *n* (%) No Yes  Aspirin  Heparin  Warfarin  Mechanical  LMWH  OtherPatient discharge location, *n* (%) Home Rehabilitation facility Other hospitalWeightbearing, *n* (%) Non-weightbearing Partial weightbearing Full weightbearingPatient aids at discharge, *n* (%) None (ambulatory) Wheelchair Walker Two crutches One crutch Cane Other*LMWH* low molecular-weight heparin

### Primary outcome analysis {#Sec10}

Our hypotheses for the primary analysis are as follows:Null hypothesis: there is no difference in reported pain between groups at 12 months measured using the VAS score.Alternative hypothesis: there is a difference in reported pain between groups at 12 months measured using the VAS score.

The primary analysis will be an analysis to compare the mean pain scores (VAS) at 12 months post-surgery adjusting for baseline VAS score (Table [4](#Tab4){ref-type="table"}). This analysis will be a multiple linear regression with VAS as the dependent variable and the following independent variables: treatment, baseline VAS score, impingement subtype, and clinical centre (all centres with fewer than 10 patients enrolled will be collapsed into a single centre for the independent variable entered into the primary analysis model). Assuming that data would be missing at random, we will use multiple imputation that will be stratified by trial arm and will include baseline demographic or prognostic variables for which we have complete data to handle missing data to enable intention-to-treat analysis \[[@CR16]\]. The treatment effect will be reported as an absolute difference in rate of pain reduction with the associated 95% confidence interval and *p* value. We will not perform a per-protocol analysis given the cross-over rate at the time of final enrollment was less than 0.5%. We will not exclude cross-overs in the final analysis. We will examine residuals to assess the model assumptions for the multiple linear regression model. All analyses will be performed using SAS version 9.4 (Cary, NC, USA).Table 4Study outcomes by treatment groupTreatment X\
*n* =Treatment Y\
*n* =Mean difference^a^ (95% CI)*p* valuemean (SD)mean (SD)Primary outcome (pain as measured by VAS)Secondary outcomes SF-12 PCS SF-12 MCS HOS iHOT-12 EQ-5D utility score*n* (%)*n* (%)Odds ratio^b^ (95% CI)*p* valueHip-related complicationsRe-operations*VAS* visual analogue scale, *PCS* physical component summary, *MCS* mental component summary, *HOS* Hip Outcome Score, *iHOT* International Hip Outcome Tool, *EQ-5D* Euroqol-5 Dimensions, SD standard deviation, CI confidence interval^a^From the multiple linear regression model^b^From the logistic regression model

### Secondary outcomes analysis {#Sec11}

We will estimate the effect of arthroscopic osteochondroplasty (intervention) versus lavage (control) on FAI patient quality of life (SF-12 mental component summary (MCS) and physical component summary (PCS)), function HOS, iHOT-12), and health utility (EQ-5D) at 12 months (Table [4](#Tab4){ref-type="table"}). Similar to the primary analysis, we will perform multiple linear regressions that include treatment, baseline score, impingement subtype, and centre as independent variables. The results will be reported as mean differences with 95% confidence intervals. We will also estimate the effect of arthroscopic osteochondroplasty (intervention) versus lavage (control) on re-operation using logistic regression that includes treatment and impingement sub-type as independent variables. If we observe enough events, we will also include centre as an independent variable. The results will be presented as the odds ratio (OR) with the 95% confidence interval. Other hip-related adverse events that were not treated operatively will be presented by randomised group. The *p* values for treatment effects for these outcomes will not be adjusted given that the secondary analyses will be exploratory. We will also report hip measurements pre-surgery/post-surgery and 12 months post-surgery by treatment group (Table [5](#Tab5){ref-type="table"}). Analyses for secondary outcomes will be complete-case analyses only.Table 5Hip measurementsTreatment XTreatment Y*n* =*n* =*n* =*n* =*n* =*n* =Pre-opPost-op12 MonthsPre-opPost-op12 MonthsAnterior hip impingement test, *n* (%) Positive NegativePosterior hip impingement test, *n* (%) Positive NegativeLog roll test, *n* (%) Positive NegativeCrossover sign, *n* (%) Positive NegativeCoxa profunda, *n* (%) Positive NegativeCoxa protrusio, *n* (%) Positive NegativeCentre-edge angle, mean (SD)Alpha angle, mean (SD)Neck shaft angle, mean (SD)Femoral offset ratio, mean (SD)Study hip range of motion, mean (SD) Flexion Extension Abduction Adduction Internal rotation (neutral) External rotation (neutral) Internal rotation (90° flexion) External rotation (90° flexion)Non-study hip range of motion, mean (SD) Flexion Extension Abduction Adduction Internal rotation (neutral) External rotation (neutral) Internal rotation (90° flexion) External rotation (90° flexion)*Pre-op* preoperative

Sensitivity analyses {#Sec12}
--------------------

We will perform sensitivity analysis of centre-effects*,* where we will repeat the primary analysis where clinical centre is not included in the model. We will also perform sensitivity analysis in regards to missing data where we include only complete cases (i.e. no imputation for missing data) \[[@CR17], [@CR18]\]. We will also conduct an adjusted analysis, which will adjust for baseline demographics, which we reasonably expect to have an impact on our trial outcomes. We will add the following to the primary analysis as independent variables: (1) age (under 40 years vs. 40 years and older), (2) any comorbidities reported at baseline, (3) onset of symptoms (acute, subacute, insidious, traumatic, non-traumatic), and (4) presence of labral tears at initial surgery. This will address any potential baseline imbalance between randomised groups.

Subgroup analyses {#Sec13}
-----------------

At the onset of the FIRST trial, we identified 4 important subgroups, which will be reported according to standard guidelines \[[@CR19]\]. We will add a main effect for the subgroup variable and the treatment by subgroup interaction to our primary model described above to assess whether the magnitude of the treatment effect is significantly different between subgroups (Fig. [2](#Fig2){ref-type="fig"}). This will be repeated for each subgroup variable. We will perform these subgroup analyses with the primary endpoint as the outcome:Severe versus moderate versus mild baseline impingement - impingement will be classified as follows: severe (alpha angle greater than 83°), moderate (alpha greater than 60°), and mild (alpha angle of less than 60°). We hypothesize that patients with severe impingement at baseline will have the greatest improvement with the osteochondroplasty procedure compared with those with moderate to mild impingement \[[@CR20]--[@CR22]\].Gender **-** we hypothesize that the osteochondroplasty procedure will perform better in men \[[@CR23], [@CR24]\].Cartilage status (grades 3 and 4 vs 1 and 2) - based on the Tonnis and Heinecke cartilage classification, we hypothesize that osteochondroplasty will perform worse in patients with worse cartilage status (i.e. grades 3 and 4) \[[@CR25]--[@CR27]\].Treatment of the labrum **-** we hypothesize that patients receiving a labral repair will perform better than those receiving a resection as part of the osteochondroplasty procedure \[[@CR28]\].Fig. 2Subgroup analyses of the primary end point, according to treatment group

If a statistically significant subgroup effect is found, we will further explore the impact of the subgroup on the secondary outcomes. No interim analyses are planned due to our desire to avoid spuriously inflated estimates of treatment effect \[[@CR29], [@CR30]\]. The Data Safety and Monitoring Committee (DSMC) meet regularly to monitor the study data for safety.

### Dissemination {#Sec14}

Upon trial completion, the primary manuscript with the 12-month follow-up results, whether positive, negative or neutral, will be submitted for peer-reviewed publication in a top medical journal. The final dataset will be shared through an open access data repository once all analyses are completed.

Trial status {#Sec15}
------------

The trial began as a pilot of 50 patients in November 2012. Upon demonstrating feasibility and securing additional funding (January 2015), these participants were rolled into the definitive trial (*N* = 220). For the definitive trial, full participant recruitment was achieved in November 2017 and the final 12-month follow-up is expected to be completed in December 2018.
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